Gabelli & Co Investment Advisers’s Tourmaline Bio TRML Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-31,050	Closed	-$1.49M	–	324
2025 Q3	$1.49M	Buy	+31,050	New	+$861K	0.24%	84

Gabelli & Co Investment Advisers's TRML Position: Q4 2025 in Review

Gabelli & Co Investment Advisers sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 31,050 shares — an estimated $1.49M sold.

Gabelli & Co Investment Advisers first reported a position in TRML in Q3 2025 and held it in 1 quarter. The position peaked at $1.49M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Gabelli & Co Investment Advisers reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 31,050 Tourmaline Bio shares in Q4 2025, an estimated $1.49M.
Gabelli & Co Investment Advisers first reported a position in Tourmaline Bio in Q3 2025 and held it in 1 quarter.
Gabelli & Co Investment Advisers's Tourmaline Bio position peaked at $1.49M in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2025, filed 5 Feb 2026.